Apixaban Intermediate CAS 503615-03-0 3-Morpholino-1-(4-Nitrophenyl)-5,6-Dihydropyridin-2(1H)-one Purity ≥99.0% (HPLC)

Short Description:

3-Morpholino-1-(4-Nitrophenyl)-5,6-Dihydropyridin-2(1H)-one

CAS: 503615-03-0

Purity: ≥99.0% (HPLC)

Appearance: Yellow Powder

Intermediate of Apixaban (CAS: 503612-47-3)

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Ruifu Chemical is the leading manufacturer of 3-Morpholino-1-(4-Nitrophenyl)-5,6-Dihydropyridin-2(1H)-one (CAS: 503615-03-0) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Apixaban intermediates, Please contact: alvin@ruifuchem.com

Apixaban Intermediates:

Chemical Properties:

Chemical Name 3-Morpholino-1-(4-Nitrophenyl)-5,6-Dihydropyridin-2(1H)-one 
Synonyms 3-(4-Morpholinyl)-1-(4-Nitrophenyl)-5,6-Dihydro-2(1H)-Pyridinone; 5,6-Dihydro-3-(4-Morpholinyl)-1-(4-Nitrophenyl)-2(1H)-Pyridinone; Apixaban Intermediate 3; Apixaban Impurity 36; Apixaban Process Impurity 1
Stock Status In Stock, Commercial Production
CAS Number 503615-03-0
Molecular Formula C15H17N3O4
Molecular Weight 303.31 g/mol
Melting Point 165.0~170.0℃ 
Boiling Point 506.5±50.0℃
Density 1.357g/mL
COA & MSDS Available
Origin Shanghai, China
Category   Intermediate of Apixaban (CAS: 503612-47-3) 
Brand Ruifu Chemical

Specifications:

Items Inspection Standards Results
Appearance Yellow Powder  Yellow Powder     
Melting Point 165.0~170.0℃ 167.0~170.0℃
Loss on Drying ≤0.50% 0.3% 
Individual Impurity (Max.) ≤0.50% 0.3%
Total Impurities ≤1.00% 0.6%
Purity / Analysis Method ≥99.0% (HPLC)  99.4% 
1 H NMR Spectrum  Consistent with Structure Complies
LC/MS Consistent with Structure Complies
Conclusion The product has been tested & complies with the given specifications

Package/Storage/Shipping:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃) and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery. 

503615-03-0 - Synthetic Route:

www.ruifuchemical.com

Advantages:

Sufficient Capacity: Sufficient facilities and technicians

Professional Service: One stop purchasing service

OEM Package: Custom package and label available

Fast Delivery: If within stock, three days delivery guaranteed

Stable Supply: Maintain reasonable stock    

Technical Support: Technology solution available

Custom Synthesis Service: Ranged from grams to kilos

High Quality: Established a complete quality assurance system

FAQ:

How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com 

15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.

Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.

Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.

Quality AssuranceStrict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.

SamplesMost products provide free samples for quality evaluation, shipping cost should be paid by customers.

Factory AuditFactory audit welcome. Please make an appointment in advance.

MOQ? No MOQ. Small order is acceptable.

Delivery Time? If within stock, three days delivery guaranteed.

TransportationBy Express (FedEx, DHL), by Air, by Sea.

Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.

Custom SynthesisCan provide custom synthesis services to best fit your research needs.

Payment TermsProforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc. 

Application:

3-Morpholino-1-(4-Nitrophenyl)-5,6-Dihydropyridin-2(1H)-one (CAS: 503615-03-0) is the intermediate for the synthesis of Apixaban (CAS: 503612-47-3).
Apixaban is a new type of oral Xa factor inhibitor jointly developed by Bristol-Myers Squibb and Pfizer. The trade name is Eratol, which is a new type of oral anticoagulant. By inhibiting an important coagulation factor Xa, Apixaban can prevent thrombin production and thrombosis.
On April 26, 2007, Bristol-Myers Squibb joined hands with Pfizer to announce the cooperation in the development of a new oral anticoagulant Apixaban owned by Bristol-Myers Squibb as an upgraded alternative to warfarin. According to the cooperation agreement, Pfizer will pay an advance payment of US $0.25 billion to Bristol-Myers Squibb to bear the 60% of the total development cost of the anticoagulant Apixaban (to be implemented from January 1, 2007), while Bristol-Myers Squibb will bear the remaining 40%, thus obtaining the right to jointly develop and sell the drug.
In May 2011, Apixaban was the first to approve the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery in 27 EU countries, Iceland and Norway.
On November 20, 2012, the European Commission approved Ererto (Apixaban) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors. Subsequently, the Canadian Food and Drug Administration, Japan, and the US FDA approved Ererto (Apixaban) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
On April 12, 2013, the new anticoagulant drug Eloto (ELIQUIS)(apixaban) jointly developed by Bristol-Myers Squibb and Pfizer was officially announced to be listed in China. Ererto is a novel oral factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement. Its listing provides a safe and effective new choice for clinical anticoagulation after orthopedic surgery, and brings good news to Chinese patients undergoing hip/knee elective replacement. Clinical studies have confirmed that compared with 40mg enoxaparin once a day, 2 times a day oral administration of Eratol (Apixaban) 2.5mg is more effective for preventing venous thromboembolism after hip or knee replacement surgery, and does not increase the risk of bleeding.   

  • Write your message here and send it to us